logo
    Docs
 

Disease Report: Alzheimer's Disease


Groups and Companies
Funding
Standard of Care
Unmet Medical Need
Novel Modalities and Combinations
Symptoms Evidence
Symptoms Targets
Pathogenesis Evidence
Pathogenesis Targets
Assays and Models

1. Hypothesis Summary:

The hypothesis posits that cognitive and functional symptoms in Alzheimer's disease (AD) primarily arise from neurodegeneration in the medial temporal lobe (MTL), which occurs in conjunction with amyloid pathology. It further suggests that while amyloid burden alone does not lead to cognitive decline, the combination of amyloid pathology and neurodegeneration is crucial for the onset of symptoms.

2. Mechanism and Evidence:

The proposed mechanism involves the interplay between amyloid-beta (Aβ) accumulation and neurodegeneration, particularly in the MTL, which includes the hippocampus—a region critical for memory and cognitive function. Evidence suggests that Aβ deposition initiates a cascade of neurodegenerative processes, including tau pathology, which ultimately leads to synaptic dysfunction and cognitive decline.
  • Evidence: Studies have shown that amyloid pathology can be detected years before clinical symptoms appear, with significant changes in tau levels and neurodegeneration following (Jia et al., 2024; PMID: 38381674). The temporal sequence of biomarker changes indicates that while Aβ accumulation is an early event, neurodegeneration and tau pathology are more closely associated with cognitive impairment.

3. Clinical Evidence:

Clinical studies have demonstrated a strong correlation between neurodegeneration in the MTL and cognitive decline in AD patients. For instance, longitudinal studies have shown that individuals with MTL atrophy exhibit significant memory deficits compared to those without such atrophy.
  • Evidence: A study by Mattsson-Carlgren et al. (2023) found that plasma biomarkers, particularly phosphorylated tau (p-tau217), were predictive of cognitive decline in cognitively unimpaired individuals with Aβ positivity, suggesting that neurodegeneration is a critical factor in the progression of cognitive symptoms (PMID: 36745413).

4. Genetic Targets and Evidence:

Genetic factors, such as the presence of the apolipoprotein E (APOE) ε4 allele, have been implicated in both amyloid accumulation and neurodegeneration. Individuals carrying this allele are at a higher risk for developing AD and exhibit earlier onset of cognitive decline.
  • Evidence: Research indicates that APOE ε4 carriers show accelerated amyloid deposition and neurodegeneration, particularly in the MTL, compared to non-carriers (Mattsson-Carlgren et al., 2023; PMID: 36745413).

5. Protein Targets and Evidence:

Key proteins involved in AD pathology include amyloid-beta and tau. The accumulation of Aβ leads to the formation of neurofibrillary tangles composed of hyperphosphorylated tau, which is associated with neurodegeneration.
  • Evidence: Studies have shown that elevated levels of p-tau in cerebrospinal fluid (CSF) correlate with neurodegeneration and cognitive decline, supporting the hypothesis that tau pathology is a critical mediator of cognitive symptoms (Ashton et al., 2024; PMID: 38252443).

6. Pathways and Evidence:

The amyloid cascade hypothesis outlines a pathway where Aβ accumulation leads to tau pathology and subsequent neurodegeneration. This pathway is supported by evidence showing that interventions targeting Aβ have not consistently resulted in cognitive improvements, suggesting that tau and neurodegeneration play significant roles.
  • Evidence: Longitudinal studies have shown that changes in tau levels and neurodegeneration precede cognitive decline, indicating that these factors are critical in the disease progression (Jia et al., 2024; PMID: 38381674).

7. Cellular Targets and Evidence:

Neuroinflammation and synaptic dysfunction are cellular processes that are exacerbated by amyloid and tau pathology. Microglial activation in response to Aβ deposition contributes to neurodegeneration and cognitive decline.
  • Evidence: Research indicates that activated microglia can exacerbate tau pathology and neuronal loss, linking cellular responses to the cognitive symptoms observed in AD (Mattsson-Carlgren et al., 2023; PMID: 36745413).

8. Tissue Targets and Evidence:

The MTL, particularly the hippocampus, is a critical tissue target in AD. Neurodegeneration in this region is closely associated with memory deficits and cognitive decline.
  • Evidence: Studies have shown that atrophy in the hippocampus correlates with cognitive impairment, highlighting the importance of this tissue in the emergence of symptoms (Jia et al., 2024; PMID: 38381674).

9. Additional Context:

While the hypothesis is supported by substantial evidence linking neurodegeneration in the MTL and amyloid pathology to cognitive decline, it is important to note that other factors, such as vascular pathology and tau aggregation, also contribute to the complexity of AD. Some studies suggest that amyloid burden alone may not be sufficient to induce cognitive decline without the presence of neurodegenerative changes (Nascimento et al., 2022; PMID: 35842055).
In conclusion, the evidence largely supports the hypothesis that cognitive and functional symptoms in AD are primarily related to neurodegeneration in the MTL, occurring alongside amyloid pathology. However, the interplay of multiple factors, including tau pathology and neuroinflammation, complicates the understanding of AD progression and symptom emergence.